Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
--------------------------------------------------------------------
Source: CNBC
Published: 2026-03-27 22:43 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Economy & Finance, Financial Markets, Business & Economy
--------------------------------------------------------------------
Snippet:
Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market, the Swiss pharmaceutical giant said Friday.
--------------------------------------------------------------------